![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
Dr. Nina Niu Sanford
@niusanford
GI Radiation Oncologist | Boston, @Princeton, @harvardmed, now @UTSWNews in Dallas | buying in bulk | @AAAS IF/THEN | Tweets=own | FCOI: rb.gy/h
ID: 1064888789200527361
https://utswmed.org/doctors/nina-sanford/ 20-11-2018 14:30:46
3,3K Tweet
6,6K Followers
1,1K Following
![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
![Ane Appelt (@cancerphysicist) 's Twitter Profile Photo Ane Appelt (@cancerphysicist) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1292836991361527808/OPbvI-wr_200x200.jpg)
![Mark Lewis, MD, FASCO (@marklewismd) 's Twitter Profile Photo Mark Lewis, MD, FASCO (@marklewismd) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1441121557602918402/xwtx7kBj_200x200.jpg)
![GI Oncology Now (@gioncnow) 's Twitter Profile Photo GI Oncology Now (@gioncnow) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1744476494951227392/u6qXmAcS_200x200.jpg)
⭐ Check out our exclusive interview with Dr. Nina Niu Sanford of UT Southwestern Medical Center on her unique experiences and insights in the gastrointestinal oncology field. ⚕️She provides insight on her specialization in radiation oncology and her work in clinical trials: buff.ly/3SDLLlC
![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
![Francisco De La Vega (@ribo.zyme@threads.net) (@ribozyme) 's Twitter Profile Photo Francisco De La Vega (@ribo.zyme@threads.net) (@ribozyme) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1365795728023384067/Oy7frYYy_200x200.jpg)
![David Sher (@davidshermd) 's Twitter Profile Photo David Sher (@davidshermd) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1115437628705341440/9Se2FaC2_200x200.jpg)
![Bryan Carmody (@jbcarmody) 's Twitter Profile Photo Bryan Carmody (@jbcarmody) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1245752899742859266/BtoUNZhG_200x200.jpg)
![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
![Lauren Henke, MD, MSCI (@lauren_henke) 's Twitter Profile Photo Lauren Henke, MD, MSCI (@lauren_henke) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1688331410627530759/AE2Qz_ci_200x200.jpg)
Dr. Nina Niu Sanford Krishan Jethwa Neil Newman Hyun Kim Completely agree. I worry we already over-treat many patients in the US, especially low risk upper rectal, and these recs will not help discourage that…. This seems like a significant over-generalization to me.
![Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1363281714022215680/4JxeUbEP_200x200.jpg)
Dr. Nina Niu Sanford Dr. Foxpaws Fauxpas Yakup Ergün Journal of the @NCCN Anant Ramaswamy Lot of data for neoa adjuvant IO for MSI high colo rectal cancer . Most of it it phase 2 data. Below is summary table for all trials in this setting .
![Dr Amol Akhade (@suyogcancer) on Twitter photo <a href="/NiuSanford/">Dr. Nina Niu Sanford</a> <a href="/imsmart420/">Dr. Foxpaws Fauxpas</a> <a href="/dr_yakupergun/">Yakup Ergün</a> <a href="/JNCCN/">Journal of the @NCCN</a> <a href="/AnantRamaswamy/">Anant Ramaswamy</a> Lot of data for neoa adjuvant IO for MSI high colo rectal cancer . Most of it it phase 2 data. Below is summary table for all trials in this setting . <a href="/NiuSanford/">Dr. Nina Niu Sanford</a> <a href="/imsmart420/">Dr. Foxpaws Fauxpas</a> <a href="/dr_yakupergun/">Yakup Ergün</a> <a href="/JNCCN/">Journal of the @NCCN</a> <a href="/AnantRamaswamy/">Anant Ramaswamy</a> Lot of data for neoa adjuvant IO for MSI high colo rectal cancer . Most of it it phase 2 data. Below is summary table for all trials in this setting .](https://pbs.twimg.com/media/GVmMRqSbgAQ5kMq.jpg)
![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
![Ryan Morse (@ryanmorseku) 's Twitter Profile Photo Ryan Morse (@ryanmorseku) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1321869602146541568/eOg6EbDH_200x200.jpg)
Dr. Nina Niu Sanford Krishan Jethwa Neil Newman Hyun Kim Curious the way PROSPECT incorporated to NCCN by only specifying non-T4: -Trial criteria did not include N2 -Required MRF margin of at least 3 mm -More formal guidelines on measuring “20%” would be helpful -No mention in NCCN of adjuvant chemo most received
![Bobby Koneru, MD (@konerumd) 's Twitter Profile Photo Bobby Koneru, MD (@konerumd) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1718262938618806272/ORuICgq4_200x200.jpg)
![Michael Chuong (@mikechuongmd) 's Twitter Profile Photo Michael Chuong (@mikechuongmd) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1657010851264581634/sCmxzbSa_200x200.jpg)
Letter to editor from Laura Dawson Jordan Kharofa Dr. Nina Niu Sanford Ali Hosni Mamen Rubio Rodriguez Regarding 1.5 T MRL pancreas planning protocol manuscript (PMID 38831754) Elective coverage should be routine It impacts planning authors.elsevier.com/sd/article/S24…
![Jeff Ryckman (@jryckman3) 's Twitter Profile Photo Jeff Ryckman (@jryckman3) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1192475881479868416/mto4fgQy_200x200.jpg)
Michael Chuong Krishan Jethwa Susannah Ellsworth DocDaviesMD Thomas P. Kole, M.D., Ph.D Todd Scarbrough James Good Austin Sim, MD JD Neil Newman Hyun Kim Cliff Robinson Freddy E Escorcia (@freddyeescorcia elsewhere) Matt Spraker Lauren Henke, MD, MSCI Updated the 5 and 15 fraction dose-escalated templates with recent feedback from upcoming contouring and prescription guidelines. Given the aggressive large bowel metrics, a range has been provided. Open to all feedback. #PancSM #Radonc Dr. Nina Niu Sanford Krishan Jethwa
![Jeff Ryckman (@jryckman3) on Twitter photo <a href="/MikeChuongMD/">Michael Chuong</a> <a href="/KrishanJethwa/">Krishan Jethwa</a> <a href="/free_radical28/">Susannah Ellsworth</a> <a href="/olusolaodavies/">DocDaviesMD</a> <a href="/drthomaskole/">Thomas P. Kole, M.D., Ph.D</a> <a href="/toddscarbrough/">Todd Scarbrough</a> <a href="/drjamesgood/">James Good</a> <a href="/A_CT_SimMDJD/">Austin Sim, MD JD</a> <a href="/nbn426/">Neil Newman</a> <a href="/adapthyun/">Hyun Kim</a> <a href="/SBRT_CR/">Cliff Robinson</a> <a href="/freddyeescorcia/">Freddy E Escorcia (@freddyeescorcia elsewhere)</a> <a href="/SprakerMDPhD/">Matt Spraker</a> <a href="/lauren_henke/">Lauren Henke, MD, MSCI</a> Updated the 5 and 15 fraction dose-escalated templates with recent feedback from upcoming contouring and prescription guidelines. Given the aggressive large bowel metrics, a range has been provided.
Open to all feedback.
#PancSM #Radonc
<a href="/NiuSanford/">Dr. Nina Niu Sanford</a> <a href="/KrishanJethwa/">Krishan Jethwa</a> <a href="/MikeChuongMD/">Michael Chuong</a> <a href="/KrishanJethwa/">Krishan Jethwa</a> <a href="/free_radical28/">Susannah Ellsworth</a> <a href="/olusolaodavies/">DocDaviesMD</a> <a href="/drthomaskole/">Thomas P. Kole, M.D., Ph.D</a> <a href="/toddscarbrough/">Todd Scarbrough</a> <a href="/drjamesgood/">James Good</a> <a href="/A_CT_SimMDJD/">Austin Sim, MD JD</a> <a href="/nbn426/">Neil Newman</a> <a href="/adapthyun/">Hyun Kim</a> <a href="/SBRT_CR/">Cliff Robinson</a> <a href="/freddyeescorcia/">Freddy E Escorcia (@freddyeescorcia elsewhere)</a> <a href="/SprakerMDPhD/">Matt Spraker</a> <a href="/lauren_henke/">Lauren Henke, MD, MSCI</a> Updated the 5 and 15 fraction dose-escalated templates with recent feedback from upcoming contouring and prescription guidelines. Given the aggressive large bowel metrics, a range has been provided.
Open to all feedback.
#PancSM #Radonc
<a href="/NiuSanford/">Dr. Nina Niu Sanford</a> <a href="/KrishanJethwa/">Krishan Jethwa</a>](https://pbs.twimg.com/media/GWQBO6lWwBA6rGJ.jpg)
![UT Health San Antonio MD Anderson (@uthealthsamda) 's Twitter Profile Photo UT Health San Antonio MD Anderson (@uthealthsamda) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1031611126901927936/EALQE-RI_200x200.jpg)
Neil Newman, MD, a radiation oncologist UT Health San Antonio MD Anderson, is part of a national study using low-dose radiation to treat osteoarthritis. Unlike cancer treatment, this therapy uses lower doses to target pain directly at the joint. Neil Newman Learn more: bit.ly/47h55eD
![UT Health San Antonio MD Anderson (@uthealthsamda) on Twitter photo Neil Newman, MD, a radiation oncologist <a href="/UTHealthSAMDA/">UT Health San Antonio MD Anderson</a>, is part of a national study using low-dose radiation to treat osteoarthritis. Unlike cancer treatment, this therapy uses lower doses to target pain directly at the joint. <a href="/nbn426/">Neil Newman</a>
Learn more: bit.ly/47h55eD Neil Newman, MD, a radiation oncologist <a href="/UTHealthSAMDA/">UT Health San Antonio MD Anderson</a>, is part of a national study using low-dose radiation to treat osteoarthritis. Unlike cancer treatment, this therapy uses lower doses to target pain directly at the joint. <a href="/nbn426/">Neil Newman</a>
Learn more: bit.ly/47h55eD](https://pbs.twimg.com/media/GWvdERuXcAAgy5Q.jpg)
![Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1663539342143369216/gC9MtFqu_200x200.jpg)
Big congrats to Laura Dawson & team for completing this symptom-based, palliative radiotherapy RCT! 8Gy x 1 ~whole liver RT improves pain in 67% Agree that all patients fitting study criteria should be offered this simple, convenient, safe & cost-effective treatment.